Lithium

Lithium

SCHEMBL488986

CC1CCCN(C)C1(C)C.[Li]

nearest known ligand 0.30

Full drug profile on Sugi Atlas →

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.30
ALDH1A1 P00352 1/20 0.30
HSD17B10 Q99714 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL125978 0.98 KDM4E (0.31) KDM4EALDH1A1HSD17B10
SCHEMBL31386632 0.95 KDM4E (0.30) KDM4EALDH1A1HSD17B10
Rubidium SCHEMBL31257199 0.95 KDM4E (0.30) KDM4EALDH1A1HSD17B10
Magnesium SCHEMBL31257200 0.95 KDM4E (0.34) KDM4EALDH1A1HSD17B10
SCHEMBL18956275 0.95 KDM4E (0.30) KDM4EALDH1A1HSD17B10
SCHEMBL31523974 0.95 KDM4E (0.30) KDM4EALDH1A1HSD17B10
Ammonia Solution, Strong SCHEMBL15018678 0.95 KDM4E (0.30) KDM4EALDH1A1HSD17B10
Hydrochloric Acid SCHEMBL5318480 0.95 KDM4E (0.30) KDM4EALDH1A1HSD17B10
SCHEMBL11741955 0.95 KDM4E (0.30) KDM4EALDH1A1HSD17B10
Calcium SCHEMBL31257197 0.95 KDM4E (0.30) KDM4EALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1292 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116813670-B Large-steric-hindrance C-C coupled palladium ligand and synthesis method thereof 西安欧得光电材料有限公司 2026-05-15 CN claimed
CN-122010807-A Preparation method of negative charge highly delocalized sulfimide alkali metal salt 华中科技大学 2026-05-12 CN claimed
US-20250214938-A1 PROCESS FOR PREPARING ((1S,2S)-2-(5-METHYLPYRIDIN-2-YL)CYCLOPROPYL)-METHANOL MERCK SHARP & DOHME LLC (US) 2025-07-03 US claimed
CN-117399070-B Chiral metal synergistic catalytic system containing chelating ligand and application of chiral metal synergistic catalytic system in asymmetric synthesis of bedaquiline 上海交通大学 2025-06-24 CN claimed
CN-119954609-A 2-Iodo-3, 4,5,6-d4Process for the preparation of phenol 广州瑞安博医药科技有限公司 2025-05-09 CN claimed
WO-2025097020-A1 PROCESS FOR POLYETHYLENE GLYCOL SYNTHESIS Design Therapeutics, Inc. (US) 2025-05-08 WO claimed
EP-4543430-A1 SYNTHESIS OF TETRAHYDRONAPHTHALENOLS AND USES THEREOF IO Therapeutics, Inc. (US) 2025-04-30 EP claimed
CN-119894883-A Methods and processes for preparing MCT4 inhibitors 维托尔股份有限公司 2025-04-25 CN claimed
CN-119735606-A Preparation method of gem-bis (boron group) -containing cyclopropane compound 南京工业大学 2025-04-01 CN claimed
CN-119731161-A Lysergic acid derivatives and methods 佛罗里达州立大学研究基金会有限公司 2025-03-28 CN claimed
CN-1370171-A Process for preparing nucleoside metabolism inhibitors IND RES LTD (NZ) 2002-09-18 CN claimed
CN-1353684-A Ether compounds, compositions and uses thereof ESPERION THERAPEUTICS INC (US) 2002-06-12 CN claimed
CN-1066723-C Intermediates for HIV protease inhibitors and process for preparing the same MERCK & CO INC (US) 2001-06-06 CN claimed
US-6207846-B1 REACTING 3-ARYL-1,1,2-TRIFLUORO-1-PROPENE WITH A REDUCING AGENT; THEN A LITHIUM BASE; THEN ARYLCHLOROSILANE COMPOUND AMERICAN CYANAMID CO. 2001-03-27 US claimed
US-6159956-A Process and intermediate compounds for the preparation of difluorovinylsilane insecticidal and acaricidal agents AMERICAN CYANAMID CO. (US) 2000-12-12 US claimed
CN-1046715-C Process for preparing HIV protease inhibitors MERCK & CO INC (US) 1999-11-24 CN claimed
CN-1046261-C Synthesis of taxol and its derivatives UNIV FLORIDA STATE (US) 1999-11-10 CN claimed
CN-1137789-A Synthesis of taxol and its derivatives UNIV FLORIDA STATE (US) 1996-12-11 CN claimed
CN-1130905-A Process for preparing HIV protease inhibitors MERCK & CO INC (US) 1996-09-11 CN claimed
CN-1130380-A Process for preparing HIV protease inhibitors MERCK & CO INC (US) 1996-09-04 CN claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250214938-A1 PROCESS FOR PREPARING ((1S,2S)-2-(5-METHYLPYRIDIN-2-YL)CYCLOPROPYL)-METHANOL DHPS, CYP2S1, CYP51A1 KDM4E 527/4885ALDH1A1 1671/4885HSD17B10 1679/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.